CRISPR Therapeutics AG

Insider buy: CRISPR Chief Medical Officer Naimish Patel adds 1,508 shares amid mixed sales, signaling confidence in gene‑editing prospects and potential rebound.

Discover how CFO Prasad Raju’s strategic buy‑sell trades reveal confidence in CRISPR’s future while offering investors short‑term gains and long‑term stability.

Insider CFO Prasad Raju’s 10b5‑1 trades show confidence in CRISPR Therapeutics; buying near $45‑$44 while selling above $60 signals a bullish, medium‑term outlook for the gene‑editing stock.